Kenneth Harrison
Director/Board Member at Claris Biotherapeutics, Inc.
Profile
Kenneth Harrison is currently a Director at Glycomine, Inc., Aristea Therapeutics, Inc., Claris Biotherapeutics, Inc., Nuvig Therapeutics, Inc., a Partner at Novo Ventures 1 A, and a Principal at Novo Ventures (US), Inc. He previously held positions as an Independent Director at Reneo Pharmaceuticals, Inc., an Independent Non-Executive Director at Edgewise Therapeutics, Inc., a Senior Manager-Market Planning at Genentech, Inc., a Partner at Mission Bay Capital Management, Inc., and a Manager-Entrepreneurship Program at California Institute For Quantitative Biosciences.
Harrison received his undergraduate degree from Texas Tech University and his doctorate from Yale School of Medicine.
Kenneth Harrison active positions
| Companies | Position | Start |
|---|---|---|
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Private Equity Investor | 2015-10-31 |
Claris Biotherapeutics, Inc.
 Claris Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Claris Biotherapeutics, Inc. engages in the manufacturing of drugs. The company was founded in 2018 and is headquartered in Jersey City, NJ. | Director/Board Member | - |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Director/Board Member | - |
Aristea Therapeutics, Inc.
 Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Director/Board Member | - |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Director/Board Member | - |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 2015-10-31 |
Former positions of Kenneth Harrison
| Companies | Position | End |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Director/Board Member | 2023-06-20 |
| RENEO PHARMACEUTICALS, INC. | Director/Board Member | 2022-01-19 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2015-10-31 |
| ░░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Kenneth Harrison
| Texas Tech University | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| RENEO PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
Mission Bay Capital Management, Inc.
 Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | Finance |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Finance |
Claris Biotherapeutics, Inc.
Claris Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Claris Biotherapeutics, Inc. engages in the manufacturing of drugs. The company was founded in 2018 and is headquartered in Jersey City, NJ. | Health Technology |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
California Institute For Quantitative Biosciences
 California Institute For Quantitative Biosciences Investment ManagersFinance Part of University of California, California Institute For Quantitative Biosciences is a biotech company that offers internships to UC students through its state-funded Qwest internship program. The company is based in San Francisco, CA and was founded in 2000. The program places students with Bakar Labs tenant companies for work experience, and four of its first cohort have already received full-time job offers from their hosts. The company conducts proof-of-concept experiments in a mouse model of ALS and offers mentoring programs to early-stage companies. | Finance |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
- Stock Market
- Insiders
- Kenneth Harrison